11 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27326332	66	Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.	Bristol-Myers Squibb
22260081	12	Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.	Universit£
18029176	66	Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.	Johnson & Johnson
22133631	76	Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.	Kyorin Pharmaceutical
19349176	137	Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.	F. Hoffmann-La Roche
16216504	8	Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.	Novartis Institutes For Biomedical Research
14584939	32	Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.	Novo Nordisk
12954061	153	Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.	Ligand Pharmaceuticals
12904063	69	Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.	Kyorin Pharmaceutical
31320147	22	Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR?)-selective agonists.	Okayama University
8474008	58	Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.	Virginia Commonwealth University